Moreover, IHC assays showed that compared with CRexo, hCRexo treatment significantly increased BCL2, phosphorylated BCL2, PKM2 and GLUT1 expression levels in tumor tissues (Figure 7E and Figure S7). The gene discussed is SLC2A1; the disease is neoplasm.